Global Peptide Synthesis Market is estimated to be valued at over US$ 1.39 billion by 2033 and register a CAGR of over 7.60% during the forecast period 2025 to 2033. 

Growing usage of peptides in pharmaceutical drugs, development of advanced peptide synthesizers and availability of funding for research and development activities related to peptides are some key driving factors of the global peptide synthesis market.

However, a lack of unified regulations for peptides used in therapy shall prove to be a major restraining factor for the market growth. 

The Asia Pacific region is a lucrative market space and this could create numerous profitable opportunities for the global peptide synthesis market to grow exponentially. Nonetheless, the issues associated with the administrative route of peptide drugs pose some tough challenges for the peptide synthesis market growth. 

The Usage of Advanced Peptide Synthesizers is Key to the Growth of the Market

Peptides are biologically diverse which is why they are used in extensive therapeutic areas. Furthermore, they are widely utilised as a potential active pharmaceutical ingredient in drug development pathways due to their high specificity, relative ease of synthesis, high biological activity, low toxicity and ready availability. Peptides generate huge sums of money through diabetes, oncology and obesity-the three most prominent therapeutic areas for peptide synthesis. As a drug modality, peptidomimetics and peptides acquire the interface between large biological drugs and small molecules with the capability to have the bioavailability of small molecules and the specificity of antibodies. 

Furthermore, peptides are chemically synthesized or expressed by recombinant systems to provide viable options for researchers for discovering, manufacturing and optimizing peptide-based drugs which are why pharmaceutical companies are prioritizing on developing these drugs. 

Global Peptide Synthesizers Market Segmentation:

By Products & Services

  • Reagents
  • Equipment
  • Services

By Reagents 

  • Resins
  • Amino acids
  • Coupling Reagents
  • Dyes and Fluorescent labelling reagents
  • Other Reagents

By Equipment 

  • Peptide Synthesizers
  • Chromatography Equipment
  • Lyophilizers

By Technology 

  • Solid-Phase Peptide Synthesis
  • Solution-Phase Peptide Synthesis
  • Hybrid & Recombinant Technology

By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Development & Manufacturing Organizations and Contract Research Organizations (CDMOs & CROs)
  • Academic & Research Institutes

By Region

  •  North America
  •  Europe
  • Asia Pacific 
  • Latin America
  •  Middle East & Africa

Asia-Pacific: Identified as a high-growth hotspot, Asia-Pacific offers scale advantages, low-cost production, and rising biotech capability—trends confirmed by FutureWise.

North America: Retains the largest market share, driven by strong pharma infrastructure, R&D investment, and advanced technologies.

Europe holds a significant share, particularly in peptide therapeutics and contract development and manufacturing organization (CDMO) activities, with ongoing investments in capacity expansion.

Major players included in the Peptide Synthesis Market:

  • Genscript Biotech Corporation
  • Thermo Fisher Scientific
  • Merck KGAA
  • Bachem Holding Ag
  • Kaneka Corporation
  • Biotage AB
  • Syngene International Limited
  • Mesa Laboratories, Inc.
  • Cem Corporation
  • Proteogenix
  • Bio-synthesis Inc.
  • Dalton Pharma Services
  • Aapptec
  • Vivitide
  • Anygen Co., Ltd.
  • CSBIO
  • Advanced Chemtech
  • Luxembourg Bio Technologies Ltd.
  • JPT Peptide Technologies Gmbh
  • Ambiopharm Inc.

Recent Developments by Leading Companies

Bachem Holding AG

  • 2024–2025 facility expansions: Expanded its GMP peptide synthesis capacity in Switzerland and the USA to support increased demand for injectable peptide therapeutics.
  • API production scale-up: Continues to increase active pharmaceutical ingredient production capacity with new and upgraded facilities in Europe and North America.

Thermo Fisher Scientific

  • 2025: Introduced fully automated peptide synthesizers and custom synthesis kits tailored for academic, preclinical, and industrial research—emphasizing rapid turnaround and scalable workflows.
  • December 2022: Acquired Protagen, boosting its peptide synthesis expertise and expanding its manufacturing footprint.

Merck KGaA (Sigma-Aldrich)

  • January 2023: Acquired Asymchem to expand its capabilities in peptide synthesis and extend its global manufacturing operations.

  • 2023 portfolio launch: Released a new line of ultra-pure peptides for cell signaling, epitope mapping, and therapeutic development, serving bioscience and CRO labs globally.

GenScript Biotech Corporation

  • 2023: Enhanced its custom peptide services by integrating AI-based design tools, improving stability and labelling options—targeted to biotech startups and academic labs

Objectives of the Study:

  • To provide with an exhaustive analysis on the Peptide Synthesis Market By Products & Services, By Reagents, By Equipment, By Technology, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com